SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is trending as investors aggressively reposition for the AI hardware supercycle, with institutional flow intensifying ahead of upcoming earnings. The community is actively discussing the stock's role in the enterprise AI infrastructure buildout, while contrasting its valuation and integration strength against competitors in the data center space.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space is experiencing high volatility as investors weigh recent strategic partnerships and expansion efforts against concerns regarding delayed financial filings and ongoing internal leadership disputes. The community remains deeply divided, with some traders optimistic about potential defense sector momentum and SpaceX IPO-related catalysts, while skeptics point to the company's lack of revenue and governance risks.

Zoracles

Zoracles is currently capturing community attention as investors debate its long-term potential against a backdrop of broader crypto market volatility and the highly anticipated government policy changes. Discussion is heavily split between those focused on short-term accumulation during recent price dips and participants highlighting the project's creator-focused utility within the Base ecosystem as a catalyst for future growth.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending following the quiet launch of Meta's 'Forum' app, with the community actively debating whether this represents a true competitive threat or just another failed attempt at cloning the platform's unique discussion model. Investors remain divided as the stock faces continued volatility, with many analyzing the company's long-term growth prospects, user-generated data value, and recent competitive landscape shifts.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is capturing significant attention following stronger-than-expected prescription numbers for its oral Wegovy pill and an increased earnings outlook, signaling a potential turnaround for the firm. Community discussion is focused on the company's ability to maintain a competitive edge through its oral drug rollout, its aggressive pipeline expansion, and the potential impact of future business development and acquisitions on its long-term market position.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is experiencing high volatility as the community remains deeply polarized between bulls anticipating a breakout and vocal bears predicting further downside. Investors are actively debating the token's long-term utility and historical price action, while monitoring broader crypto sector catalysts like upcoming regulatory clarity and shifts in staking demand.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is trending as it becomes the center of a heated debate between retail investors chasing the photonics infrastructure supercycle and critics warning of extreme valuation bubbles and potential market manipulation. While supporters point to the stock's role as a critical gatekeeper for Indium Phosphide substrates in AI data centers, skeptics are aggressively highlighting a lack of consistent profitability, heavy insider selling, and the upcoming shareholder vote regarding a significant increase in authorized shares.

Hyliion Holdings Corp. engages in the development of sustainable electricity-producing technology. It focuses on providing modular power plant technology that can operate on various fuel sources through the KARNO power module. The company was founded by Thomas J. Healy in 2015 and is headquartered in Cedar Park, TX.

Hyliion Holdings Corporation - Ordinary Shares - Class A

Hyliion Holdings Corp

Hyliion Holdings Corp is experiencing significant upward momentum as investors speculate on the commercial scalability of its KARNO power technology for AI data centers and military applications. The community is actively discussing strong volume trends, institutional interest, and anticipation surrounding upcoming earnings and potential contract announcements, while keeping a close eye on the stock's ability to maintain its recent price gains.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is currently trending as investors focus on the upcoming earnings report and the company's progress toward commercial scaling of its silicon-anode battery technology for wearables and drones. The community is actively debating the significance of recent leadership appointments and potential qualification updates, balancing long-term technological optimism against frustration over past project timelines and stock performance.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors react to strong Q1 results, characterized by a massive earnings and revenue beat driven by rapid demand for Zepbound and Mounjaro. The community is actively discussing the company's raised full-year guidance and the competitive implications of its expanding GLP-1 and oncology portfolios against key rivals like Novo Nordisk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates...

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates CalciMedica Reports 2025 Financial Results and Provides Clinical Updates PR Newswire LA JOLLA, Calif., March 3, 2026 Internal...

How Is The Market Feeling About CalciMedica Inc?

CALC Stock Slumped 76% On Wednesday — Here’s Why

Equity

CalciMedica said that it has decided to discontinue the trial evaluating its lead product candidate Auxora in patients with Stage 2 or Stage 3 acute kidney injury following a committee recommendation. 


CalciMedica (NASDAQ:CALC) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded CalciMedica to a "sell" rating in a report on Saturday...

CalciMedica (NASDAQ:CALC) Trading Down 2.1% - Time to Sell?

CalciMedica (NASDAQ:CALC) Stock Price Down 2.1% - Time to Sell...

Stonepine Capital Management LLC Has $136,000 Stock Position in CalciMedica Inc. $CALC

Stonepine Capital Management LLC lowered its stake in shares of CalciMedica Inc. (NASDAQ:CALC - Free Report) by 76.9% during the second quarter, according to the company in its most recent filing...

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates...

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension CalciMedica Announces Publication in...

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora CalciMedica and Telperian Announce Collaboration to...

CalciMedica, Inc. is a clinical-stage biopharmaceutical company, which engages in developing therapies for life-threatening inflammatory diseases. The firm's product candidate, Auxora, helps in treating acute pancreatitis and asparaginase-associated pancreatitis. The company was founded by Kenneth A. Stauderman and Gonul Velicelebi in 2007 and is headquartered in La Jolla, CA.

CALC
CalciMedica Inc

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest CALC News

CALCCalciMedica Inc